CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mehmud Faisal

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 125,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 125,000 options Exercise price: $0.50 per share Underlying shares: 125,000 common shares +3 more

6 metrics

Options granted 125,000 options Stock Option (right to buy) grant to CMO

Exercise price $0.50 per share Conversion or exercise price for options

Underlying shares 125,000 common shares Shares underlying granted stock options

Post-grant option holdings 125,000 options Total options held following transaction

Exercise date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Scheduled options expiration

Key Terms

Stock Option (right to buy), exercise price, underlying security, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price set at 0.5000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: "Common Shares""

expiration date financial

"expiration_date recorded as 2031-03-27"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehmud Faisal

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		125,000		03/26/2027	03/27/2031	Common Shares	125,000	$0	125,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Faisal Mehmud	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) report for Mehmud Faisal?

Medicus Pharma reported that Chief Medical Officer Mehmud Faisal received a grant of 125,000 stock options. Each option allows him to buy one common share at a fixed $0.50 exercise price, providing potential equity-based compensation if the share price rises.

What are the key terms of Mehmud Faisal’s stock options at Medicus Pharma (MDCX)?

The grant covers 125,000 stock options with an exercise price of $0.50 per share. The options become exercisable on March 26, 2027 and expire on March 27, 2031, giving a defined window for potential exercise into common shares.

Is the Medicus Pharma (MDCX) transaction an insider purchase or a compensation grant?

The transaction is a compensation grant, not an open-market purchase. The Form 4 shows an “A” code for grant or award and describes 125,000 stock options granted to Chief Medical Officer Mehmud Faisal at a $0.50 exercise price, with no purchase price paid at grant.

How many securities does Mehmud Faisal hold after this Medicus Pharma (MDCX) option grant?

After the transaction, Mehmud Faisal holds 125,000 stock options directly. Each option is linked to one underlying common share, giving him the right, but not the obligation, to buy those shares at $0.50 before the March 27, 2031 expiration date.

When can the Medicus Pharma (MDCX) stock options granted to Mehmud Faisal be exercised?

The options become exercisable on March 26, 2027, according to the Form 4. From that date until their March 27, 2031 expiration, Mehmud Faisal can choose to exercise them at the fixed $0.50 per-share exercise price if conditions are favorable.